SFCM
TSHA icon

Seven Fleet Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Seven Fleet Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.8M Buy
625,708
+458,485
+274% +$2.13M 0.88% 29
2025
Q4 		$920K Buy
+167,223
New +$812K 0.62% 30

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Seven Fleet Capital Management's TSHA Position: Q1 2026 in Review

Seven Fleet Capital Management increased its Taysha Gene Therapies (TSHA) stake by 274% in Q1 2026, buying an estimated $2.13M and bringing the position to 625,708 shares worth $2.8M. The position accounts for 0.88% of the portfolio, ranked #29.

Seven Fleet Capital Management first reported a position in TSHA in Q4 2025 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Seven Fleet Capital Management held 625,708 shares of Taysha Gene Therapies worth $2.8M as of Q1 2026.
  • Seven Fleet Capital Management bought 458,485 Taysha Gene Therapies shares in Q1 2026, an estimated $2.13M.
  • Taysha Gene Therapies made up 0.88% of Seven Fleet Capital Management's portfolio in Q1 2026, its #29 holding.
  • Seven Fleet Capital Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.